Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tablets × Thoracic × Clear all

Phase

Phase 1/2 2 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11 Other hematologic neoplasm 5 Lymphoid 4 Gastrointestinal 4 Plasma cell 3 Dermatologic 3 Myeloid 2 Thoracic 1 Other 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Classical hematology 1 CNS 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 447 Cisplatin 342 Pemetrexed 339 Paclitaxel 226 Docetaxel 215 Gemcitabine 185 pembrolizumab 161 Bevacizumab 160 Radiotherapy 156 Erlotinib Hydrochloride 150 Etoposide 120 durvalumab 116 Nivolumab 109 Drug Therapy 102 osimertinib 85 atezolizumab 77 Gefitinib 63 Vinorelbine 61 Radiosurgery 60 anlotinib 50 tislelizumab 42 Irinotecan 42 Ipilimumab 42 130-nm albumin-bound paclitaxel 42 Surgical Procedures, Operative 41 Topotecan 39 Taxes 39 apatinib 38 Magnetic Resonance Spectroscopy 38 Albumin-Bound Paclitaxel 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00080080 2007-06-08

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Point Therapeutics

Phase 2 Completed

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡